Biomarkers in acute myeloid leukemia: From state of the art in risk classification to future challenges of RNA editing as disease predictor and therapy target
Acute Myeloid Leukemia (AML) is currently diagnosed based on morphological assessment of myeloid cells’ features, immunophenotypic characterization of specific cell surface and intracellular markers, conventional cytogenetic testing and screening for genetic abnormalities in bone marrow and peripher...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-12-01
|
| Series: | Aspects of Molecular Medicine |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2949688823000230 |
| _version_ | 1797237889370685440 |
|---|---|
| author | Alberto Quattrocchi Luca Vincenzo Cappelli Giovanna De Simone Elisabetta De Marinis Martina Gentile Tecla Gasperi Alessandro Pulsoni Paolo Ascenzi Clara Nervi |
| author_facet | Alberto Quattrocchi Luca Vincenzo Cappelli Giovanna De Simone Elisabetta De Marinis Martina Gentile Tecla Gasperi Alessandro Pulsoni Paolo Ascenzi Clara Nervi |
| author_sort | Alberto Quattrocchi |
| collection | DOAJ |
| description | Acute Myeloid Leukemia (AML) is currently diagnosed based on morphological assessment of myeloid cells’ features, immunophenotypic characterization of specific cell surface and intracellular markers, conventional cytogenetic testing and screening for genetic abnormalities in bone marrow and peripheral blood specimens. In recent years new technologies have shed light on the complexity and heterogeneity of this elusive leukemia and are providing useful biomarkers, predictive of prognosis in AML patients. Hence, technological efforts are being made in order to identify more accurate AML biomarkers also useful to track minimal residual disease at the various follow-up times. This remains an unmet need that, together with the intrinsic tumor features of AML, results in the highest death rate of all leukemias and a 5-year overall survival <50%. This review provides insights into the state-of-the-art of AML-related biomarkers and their role in clinical practice as prognostic indicators, minimal residual disease detection or candidates for targeted therapy. In addition, we report modifications of RNA epitranscriptome during normal hematopoiesis that are de-regulated in AML, recently revealed by new and more sophisticated techniques. We focus on alterations of m6A modifications on mRNAs and of enzymes catalyzing them, which have been reported to affect normal hematopoiesis and leukemogenesis and are providing novel promising biomarkers for AML risk assessment and newly druggable targets for treatment. |
| first_indexed | 2024-04-24T17:26:55Z |
| format | Article |
| id | doaj.art-577c7d6a7f1847548268c6dd2f2854bd |
| institution | Directory Open Access Journal |
| issn | 2949-6888 |
| language | English |
| last_indexed | 2024-04-24T17:26:55Z |
| publishDate | 2023-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Aspects of Molecular Medicine |
| spelling | doaj.art-577c7d6a7f1847548268c6dd2f2854bd2024-03-28T06:39:49ZengElsevierAspects of Molecular Medicine2949-68882023-12-012100023Biomarkers in acute myeloid leukemia: From state of the art in risk classification to future challenges of RNA editing as disease predictor and therapy targetAlberto Quattrocchi0Luca Vincenzo Cappelli1Giovanna De Simone2Elisabetta De Marinis3Martina Gentile4Tecla Gasperi5Alessandro Pulsoni6Paolo Ascenzi7Clara Nervi8Department of Medical-Surgical Sciences and Biotechnologies, University “La Sapienza'', Rome, ItalyHematology, Department of Translational and Precision Medicine, University “La Sapienza'', Rome, ItalyDepartment of Sciences, Roma Tre University, Rome, ItalyDepartment of Medical-Surgical Sciences and Biotechnologies, University “La Sapienza'', Rome, ItalyDepartment of Medical-Surgical Sciences and Biotechnologies, University “La Sapienza'', Rome, ItalyDepartment of Sciences, Roma Tre University, Rome, ItalyHematology, Department of Translational and Precision Medicine, University “La Sapienza'', Rome, Italy; Department of Hematology, S.M. Goretti Hospital, Polo Universitario Pontino, 04100, Latina, ItalyDepartment of Sciences, Roma Tre University, Rome, Italy; Accademia Nazionale Dei Lincei, Rome, ItalyDepartment of Medical-Surgical Sciences and Biotechnologies, University “La Sapienza'', Rome, Italy; Corresponding author.Acute Myeloid Leukemia (AML) is currently diagnosed based on morphological assessment of myeloid cells’ features, immunophenotypic characterization of specific cell surface and intracellular markers, conventional cytogenetic testing and screening for genetic abnormalities in bone marrow and peripheral blood specimens. In recent years new technologies have shed light on the complexity and heterogeneity of this elusive leukemia and are providing useful biomarkers, predictive of prognosis in AML patients. Hence, technological efforts are being made in order to identify more accurate AML biomarkers also useful to track minimal residual disease at the various follow-up times. This remains an unmet need that, together with the intrinsic tumor features of AML, results in the highest death rate of all leukemias and a 5-year overall survival <50%. This review provides insights into the state-of-the-art of AML-related biomarkers and their role in clinical practice as prognostic indicators, minimal residual disease detection or candidates for targeted therapy. In addition, we report modifications of RNA epitranscriptome during normal hematopoiesis that are de-regulated in AML, recently revealed by new and more sophisticated techniques. We focus on alterations of m6A modifications on mRNAs and of enzymes catalyzing them, which have been reported to affect normal hematopoiesis and leukemogenesis and are providing novel promising biomarkers for AML risk assessment and newly druggable targets for treatment.http://www.sciencedirect.com/science/article/pii/S2949688823000230HematopoiesisLeukemiaAML biomarkersAML risk classificationMinimal residual disease detectionEpitranscriptome |
| spellingShingle | Alberto Quattrocchi Luca Vincenzo Cappelli Giovanna De Simone Elisabetta De Marinis Martina Gentile Tecla Gasperi Alessandro Pulsoni Paolo Ascenzi Clara Nervi Biomarkers in acute myeloid leukemia: From state of the art in risk classification to future challenges of RNA editing as disease predictor and therapy target Aspects of Molecular Medicine Hematopoiesis Leukemia AML biomarkers AML risk classification Minimal residual disease detection Epitranscriptome |
| title | Biomarkers in acute myeloid leukemia: From state of the art in risk classification to future challenges of RNA editing as disease predictor and therapy target |
| title_full | Biomarkers in acute myeloid leukemia: From state of the art in risk classification to future challenges of RNA editing as disease predictor and therapy target |
| title_fullStr | Biomarkers in acute myeloid leukemia: From state of the art in risk classification to future challenges of RNA editing as disease predictor and therapy target |
| title_full_unstemmed | Biomarkers in acute myeloid leukemia: From state of the art in risk classification to future challenges of RNA editing as disease predictor and therapy target |
| title_short | Biomarkers in acute myeloid leukemia: From state of the art in risk classification to future challenges of RNA editing as disease predictor and therapy target |
| title_sort | biomarkers in acute myeloid leukemia from state of the art in risk classification to future challenges of rna editing as disease predictor and therapy target |
| topic | Hematopoiesis Leukemia AML biomarkers AML risk classification Minimal residual disease detection Epitranscriptome |
| url | http://www.sciencedirect.com/science/article/pii/S2949688823000230 |
| work_keys_str_mv | AT albertoquattrocchi biomarkersinacutemyeloidleukemiafromstateoftheartinriskclassificationtofuturechallengesofrnaeditingasdiseasepredictorandtherapytarget AT lucavincenzocappelli biomarkersinacutemyeloidleukemiafromstateoftheartinriskclassificationtofuturechallengesofrnaeditingasdiseasepredictorandtherapytarget AT giovannadesimone biomarkersinacutemyeloidleukemiafromstateoftheartinriskclassificationtofuturechallengesofrnaeditingasdiseasepredictorandtherapytarget AT elisabettademarinis biomarkersinacutemyeloidleukemiafromstateoftheartinriskclassificationtofuturechallengesofrnaeditingasdiseasepredictorandtherapytarget AT martinagentile biomarkersinacutemyeloidleukemiafromstateoftheartinriskclassificationtofuturechallengesofrnaeditingasdiseasepredictorandtherapytarget AT teclagasperi biomarkersinacutemyeloidleukemiafromstateoftheartinriskclassificationtofuturechallengesofrnaeditingasdiseasepredictorandtherapytarget AT alessandropulsoni biomarkersinacutemyeloidleukemiafromstateoftheartinriskclassificationtofuturechallengesofrnaeditingasdiseasepredictorandtherapytarget AT paoloascenzi biomarkersinacutemyeloidleukemiafromstateoftheartinriskclassificationtofuturechallengesofrnaeditingasdiseasepredictorandtherapytarget AT claranervi biomarkersinacutemyeloidleukemiafromstateoftheartinriskclassificationtofuturechallengesofrnaeditingasdiseasepredictorandtherapytarget |